AbbVie Inc.
BG ˙ BUL ˙ US00287Y1091
SecurityBG:4AB / AbbVie Inc.
InstitutionCambridge Financial Group, Inc.
Latest Disclosed Ownership37,166 shares
Latest Disclosed Value $ 8,083,233
Cambridge Financial Group, Inc. reports 0.96% increase in ownership of 4AB / AbbVie Inc.

On May 13, 2026 - Cambridge Financial Group, Inc. filed a 13F-HR form disclosing ownership of 37,166 shares of AbbVie Inc. (BG:4AB) valued at $8,083,233 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 36,811 shares of AbbVie Inc.. This represents a change in shares of 0.96% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-13 2026-03-31 13F AbbVie COM 00287Y109 37,166 355 0.96 8,083 -3.89 3.0231
2026-02-13 2025-12-31 13F AbbVie COM 00287Y109 36,811 -917 -2.43 8,411 -3.72 3.2128
2025-11-14 2025-09-30 13F AbbVie COM 00287Y109 37,728 10,431 38.21 8,736 72.42 3.3870
2025-08-07 2025-06-30 13F AbbVie COM 00287Y109 27,297 -10,706 -28.17 5,067 -36.37 2.5558
2025-05-13 2025-03-31 13F AbbVie COM 00287Y109 38,003 -300 -0.78 7,962 16.99 3.4586
2025-02-12 2024-12-31 13F AbbVie COM 00287Y109 38,303 2,322 6.45 6,806 10.29 2.8118
2024-08-12 2024-06-30 13F AbbVie COM 00287Y109 35,981 2,255 6.69 6,171 0.49 2.7747
2024-05-13 2024-03-31 13F AbbVie COM 00287Y109 33,726 2,040 6.44 6,142 25.07 2.7208
2024-02-06 2023-12-31 13F AbbVie COM 00287Y109 31,686 -2,634 -7.67 4,910 -4.01 2.4558
2023-11-13 2023-09-30 13F AbbVie COM 00287Y109 34,320 2,832 8.99 5,116 0.53 2.7876
2023-02-15 2022-12-31 13F AbbVie COM 00287Y109 31,488 -2,085 -6.21 5,089 12.94 2.8395
2022-11-07 2022-09-30 13F AbbVie COM 00287Y109 33,573 33,573 4,506 2.7110
2016-02-17 2015-12-31 13F AbbVie COM 00287Y109 0 -90,488 -100.00 0 -100.00
2015-11-12 2015-09-30 13F AbbVie COM 00287Y109 90,488 -4,470 -4.71 4,923 -22.84 2.9437
2015-08-10 2015-06-30 13F AbbVie COM 00287Y109 94,958 779 0.83 6,380 15.73 3.3984
2015-05-04 2015-03-31 13F AbbVie COM 00287Y109 94,179 94,179 5,513 2.7298
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.